Article first published online: 22 Jun 2004
Background Topical corticosteroids decrease collagen synthesis during short‐term treatment and can induce skin atrophy when applied over the long term. In contrast, short‐term tacrolimus ointment therapy does not affect collagen synthesis.
Objectives Our aim was to evaluate the long‐term effects of 0·1% tacrolimus ointment on collagen synthesis and on skin thickness in adults with moderate to severe atopic dermatitis (AD) and to compare the findings with the effects of conventional steroid‐based therapy.
Methods Fifty‐six patients with AD were treated with 0·1% tacrolimus ointment in a 1‐year, open‐label, prospective clinical trial. Thirty‐six patients with AD applied conventional steroid‐based therapy and 27 healthy subjects were recruited as controls. The primary endpoint was the change in levels of procollagen propeptides I and III measured by radioimmunoassay between baseline and month 12. Additional endpoints included the change in skin thickness measured by ultrasound between baseline and month 12.
Results Procollagen propeptide baseline values were significantly lower in the group to be treated with tacrolimus ointment than in healthy controls. One‐year treatment with tacrolimus ointment was associated with an increase in collagen synthesis; the median increase in combined procollagen propeptide levels was 272 µg L−1 (+ 140·9%, P < 0·001) and was accompanied by a significant increase in skin thickness. In three patients with visible skin atrophy, this condition ameliorated. Corticosteroid‐based therapy had no significant effect on collagen synthesis; the median increase in combined procollagen propeptide levels was 11 µg L−1 (+ 3·9%). A significant reduction in skin thickness was demonstrated.
Conclusions Long‐term tacrolimus ointment therapy in patients with AD is nonatrophogenic and reverses corticosteroid‐induced skin atrophy.Read moreRead more (PDF)
08 Dec 2019
An unusual case of mycosis fungoides with cerebral involvement, which achieved a durable complete remission after autologous stem-cell transplantation and interferon alfa-2a maintenance therapy. https://t.co/LCZbpZwDkc #CTCL #interferon https://t.co/UA8uMiBvI5
07 Dec 2019
31M born in Cape Verde presented w/ 3/52 hx of 7cm bosselated & exulcerated plaque w/ rapid growth & bleeding, assoc. w/ wt loss, fatigue & occasional cough. PCR detected Bartonella spp DNA and also tested +ve for HIV. What's your diagnosis? https://t.co/vC2R8lz0zc #medderm #BJD https://t.co/d8f75TZbhn
06 Dec 2019
RT The British Association of Dermatologists @HealthySkin4All: New @BrJDermatol research investigated the genetic basis of fibrosis in recessive dystrophic epidermolysis bullosa. This finding could lead to possible future treatment. https://t.co/WmYsCGncdW @CharityDEBRA @Wiley_Health https://t.co/wRgfgUk3jT